VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024.

Revenue
−85.3%
EPS
−75.0%
Free cash flow
−57.2%

Quarter to September 2026, against a year earlier

0.37 0.03 −7.50%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
−2.7×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Jun '17
Revenue
237.26 28.70 7.38 0.11 0.89 4.05 9.86 4.16 5.84 8.90
Revenue Growth
726.68% 288.94% 6,796.26% (88.00%) (77.95%) (58.97%) 137.12% (28.77%) (34.39%) (4.30%)
Gross Profit
237.26 28.70 7.38 0.11 0.89 4.05 9.86 4.16 5.84 8.90
Operating Income
18.07 (66.29) (83.35) (114.59) (72.75) (30.17) (15.78) (21.76) (10.01) (27.50)
EBT
16.80 (66.69) (82.20) (107.69) (70.36) (31.98) (18.15) (17.90) (9.58) (29.10)
Income after Tax
16.33 (66.95) (82.46) (107.76) (70.47) (32.22) (18.64) (18.01) (9.58) (29.40)
Net Income Common
16.33 (66.95) (82.46) (107.76) (70.47) (32.22) (18.64) (18.35) (12.46) (29.40)
EPS (Diluted)
0.07 (0.33) (0.57) (0.84) (0.58) (0.36) (0.86) (2.90) (91.65) (8.37)
Shares (Diluted, Weighted)
230.35 202.14 144.82 127.68 121.45 88.30 21.57 6.32 0.14 3.51
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBIT Margin
7.62% (230.99%) (1,129.52%) (107,090.65%) (8,156.05%) (745.67%) (160.06%) (523.11%) (171.52%) (308.99%)
Net Profit Margin
6.88% (233.27%) (1,117.56%) (100,708.41%) (7,900.22%) (796.34%) (189.06%) (441.12%) (213.39%) (330.34%)
Free Cash Flow Margin
3.19% (157.90%) (978.51%) (97,551.40%) (7,285.76%) (617.15%) (141.35%) (366.79%) (172.75%) (337.08%)
EBITDA
26.38 (58.20) (75.38) (108.94) (68.46) (27.46) (12.19) (18.53) (9.47) (27.40)
EBIT
18.07 (66.29) (83.35) (114.59) (72.75) (30.17) (15.78) (21.76) (10.01) (27.50)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 5 Nov 2026